Stockscreener 앱 받기
3.61
26.89%
0.765
전일 마감가:
$2.845
열려 있는:
$2.85
하루 거래량:
955.10K
Relative Volume:
9.90
시가총액:
$67.11M
수익:
$420.00K
순이익/손실:
$-26.98M
주가수익비율:
-0.8653
EPS:
-4.1721
순현금흐름:
$-32.01M
1주 성능:
+46.15%
1개월 성능:
+33.21%
6개월 성능:
-87.52%
1년 성능:
-98.30%
1일 변동 폭
$2.85
$3.66
1주일 범위
$2.4701
$3.66
52주 변동 폭
$2.03
$1,030.00
칼라 파마슈티컬스 Stock (KALA) Company Profile
명칭
Kala Bio Inc
전화
781-996-5252
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
3.61 | 67.11M | 420.00K | -26.98M | -32.01M | -4.1721 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | 개시 | Mizuho | Outperform |
| 2025-07-11 | 개시 | Ladenburg Thalmann | Buy |
| 2022-03-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-07-23 | 개시 | Northland Capital | Outperform |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-27 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-09 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 개시 | Jefferies | Buy |
모두보기
칼라 파마슈티컬스 주식(KALA)의 최신 뉴스
KALA BIO Inc (KALA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
KALA BIO Inc (KALA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KALA BIO Inc (KALA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KALA BIO Inc (KALA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
KALA BIO Inc (KALA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
KALA BIO Inc (KALA) Institutional Confidence - TradingKey
KALA BIO Inc (KALA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
KALA BIO Inc (KALA) Valuation: PE, PB & Fair Value Analysis - TradingKey
KALA BIO Inc (KALA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
KALA BIO Inc. Surges 6.5% as Biotech Momentum Builds: Testing Key Resistance at $2.76Resistance Breakout Stocks - newsline.com
KALA Q4 2025 Earnings: Narrowed Loss Drives 6.5% Stock GainQuarterly Earnings Report - newsline.com
KALA BIO (NASDAQ: KALA) registers $350M shelf; 1-for-50 reverse split recorded - Stock Titan
KALA BIO Inc. (KALA) Holds Steady Near Support Amid Minimal Price MovementMoving Average Ribbon - newsline.com
KALA BIO (KALA) Holds Steady Near $2.39 Amid Tight Trading RangeUpthrust Pattern - newsline.com
KALA BIO Surges 11%: Approaching Key Resistance at $2.40Wave Truncation - newsline.com
KALA BIO INC (KALA) Stock Chart - ChartMill
KALA Stock Price, Quote & Chart | KALA BIO INC (NASDAQ:KALA) - ChartMill
KALA BIO Q4 2025 Earnings: Wider-Than-Expected Loss but Narrower EPS Surprise Drives Mixed Sentiment - newsline.com
Net margin % of KALA BIO, Inc. – LSX:A4243T - TradingView
KALA BIO Shares Slide Over 6% Amid Light Trading and Sector PressureVolatility Term Structure - newsline.com
KALA BIO (KALA) Smashes Q4 2025 Views with $-33.50 EPSNegative Surprise Momentum - thelegaladvocate.com
KALA BIO (KALA) Q4 2025 Earnings Beat: Revenue $N/A, EPS $-33.50Free Cash Flow Trends - newsline.com
Kala Bio (FRA:27F) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2026) - GuruFocus
Red Light Holland Corp (OP: TRUFF - FinancialContent
KALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 mark - MSN
KALA BIO (KALA) files 13G/A: Baker Bros. reports 2,312 shares post-split - Stock Titan
KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary - TradingView
KALA BIO: Q1 Earnings Snapshot - 10TV
KALA: Q1 2026 net loss fell to $1.6M as focus shifted to AI platform and cost reductions - TradingView
KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
KALA BIO (NASDAQ: KALA) slashes R&D spend and pivots to Researgency AI platform - Stock Titan
Exclusive: Penny stock Kala Bio transitions to revenue model with AI platform launch - MSN
Total assets of KALA BIO, Inc. – LSX:A4243T - TradingView
Discontinued operations of KALA BIO, Inc. – TRADEGATE:27F - TradingView
Cash from operating activities of KALA BIO, Inc. – FWB:27F - TradingView
Asset turnover of KALA BIO, Inc. – FWB:27F - TradingView
Working capital per share of KALA BIO, Inc. – FWB:27F - TradingView
Price to book ratio of KALA BIO, Inc. – FWB:27F - TradingView
KALA BIO, Inc. Balance Sheet – TRADEGATE:27F - TradingView
Discontinued operations of KALA BIO, Inc. – LSX:A4243T - TradingView
Dilution adjustment of KALA BIO, Inc. – GETTEX:27F - TradingView
KALA BIO, Inc. Balance Sheet – LS:A4243T - TradingView
KALA BIO, Inc. Balance Sheet – GETTEX:27F - TradingView
Discontinued operations of KALA BIO, Inc. – FWB:27F - TradingView
Enterprise value to EBITDA ratio of KALA BIO, Inc. – FWB:27F - TradingView
KALA BIO, Inc. Earnings and Revenue – MUN:27F - TradingView
Why Kala Bio’s Stock Is Sinking Again - TipRanks
CapEx per share of KALA BIO INC. O.N. – MUN:27F - TradingView
EBIT per share of KALA BIO INC. O.N. – MUN:27F - TradingView
Free cash flow per share of KALA BIO INC. O.N. – MUN:27F - TradingView
Long term debt to total equity ratio of KALA BIO INC. O.N. – MUN:27F - TradingView
칼라 파마슈티컬스 (KALA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):